胰腺癌同源重组缺陷患病率的系统评价与荟萃分析
结果显示基因层面BRCA2突变率最高(胚系3.8%、体细胞3.5%),而基于基因组瘢痕等替代标志物定义的HRD患病率可达24%-44%,高于靶向测序的14.5%-16.5%。作者建议对所有PDAC患者提供整合胚系与体细胞分析的普遍HRD筛查,并呼吁统一HRD定义。
要点
- 基因层面HRD突变以BRCA2最常见,胚系3.8%、体细胞3.5%,ATM胚系约2%。
- 基因组瘢痕等替代标志物识别的HRD比例高于单纯基因层面分析。
- 建议所有PDAC患者接受整合胚系与体细胞的普遍HRD筛查。
核心结论
- 基于替代标志物的HRD检测可识别出比基因层面分析更大比例的患者存在HRD。
- 有必要统一HRD定义,并验证用于治疗选择的最佳生物标志物。
- 应所有PDAC患者提供整合体细胞与胚系分析的普遍HRD筛查。
研究设计与样本
- 系统评价与患病率荟萃分析,检索PubMed、Scopus、Cochrane Library数据库及在线肿瘤基因组数据集。
- 采用随机效应模型与Freeman-Tukey转换进行分析,PROSPERO注册号为CRD42020190813。
主要发现
- 胚系与体细胞突变合计患病率:BRCA1 0.9%、BRCA2 3.5%、PALB2 0.2%、ATM 2.2%、CHEK2 0.3%、FANC 0.5%、RAD51 0.0%、ATR 0.1%。
- 胚系突变患病率:BRCA1 0.9%(Ashkenazi犹太人2.4%)、BRCA2 3.8%(Ashkenazi犹太人8.2%)、PALB2 0.2%、ATM 2%、CHEK2 0.3%、FANC 0.4%。
- 散发性与家族性病例之间未发现显著差异。
- 靶向二代测序定义的HRD患病率为14.5%-16.5%,全基因组或全外显子测序结合基因组瘢痕等分析为24%-44%。
临床怎么用
- 对胰腺导管腺癌患者可考虑整合胚系与体细胞分析的普遍HRD筛查。
- 解读HRD时应认识到检测方法不同(靶向测序与全基因组/全外显子测序)患病率差异明显。
- 家族史阴性不能排除胚系HRD突变,散发性与家族性病例患病率无显著差异。
局限性
- 研究未涉及各检测方法间HRD定义与判读标准的统一问题,作者明确指出需harmonize HRD定义。
- 替代标志物(基因组瘢痕、突变特征)作为HRD替代指标的治疗选择价值仍需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of the prevalence of HRD in PDAC from PubMed, Scopus, and Cochrane Library databases, and online cancer genomic data sets. The main outcome was pooled prevalence of somatic and germline mutations in the better characterized HRD genes (BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, RAD51, and the FANC genes). The secondary outcomes were prevalence of germline mutations overall, and in sporadic and familial cases; prevalence of germline BRCA1/2 mutations in Ashkenazi Jewish (AJ); and prevalence of HRD based on other definitions (ie, alterations in other genes, genomic scars, and mutational signatures). Random-effects modeling with the Freeman-Tukey transformation was used for the analyses. PROSPERO registration number: (CRD42020190813). RESULTS: Sixty studies with 21,842 participants were included in the systematic review and 57 in the meta-analysis. Prevalence of germline and somatic mutations was BRCA1: 0.9%, BRCA2: 3.5%, PALB2: 0.2%, ATM: 2.2%, CHEK2: 0.3%, FANC: 0.5%, RAD51: 0.0%, and ATR: 0.1%. Prevalence of germline mutations was BRCA1: 0.9% (2.4% in AJ), BRCA2: 3.8% (8.2% in AJ), PALB2: 0.2%, ATM: 2%, CHEK2: 0.3%, and FANC: 0.4%. No significant differences between sporadic and familial cases were identified. HRD prevalence ranged between 14.5%-16.5% through targeted next-generation sequencing and 24%-44% through whole-genome or whole-exome sequencing allowing complementary genomic analysis, including genomic scars and other signatures (surrogate markers of HRD). CONCLUSION: Surrogate readouts of HRD identify a greater proportion of patients with HRD than analyses limited to gene-level approaches. There is a clear need to harmonize HRD definitions and to validate the optimal biomarker for treatment selection. Universal HRD screening including integrated somatic and germline analysis should be offered to all patients with PDAC.
引用
- Casolino R, Paiella S, Azzolina D, et al. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. J Clin Oncol. 2021. PMID: 34197182. doi:10.1200/JCO.20.03238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。